Skip to content
MedsAcross

Medicine

Alvesco 160 mcg inhaler

Ciclesonide · Inhalation · Covis Pharma
Available on requestPrescription onlyUS FDA

Alvesco 160 mcg inhaler is a prescription medicine containing Ciclesonide for inhalation use, marketed by Covis Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 25°C (77°F). Excursions between 15°C and 30°C (59°F and 86°F) are…

Key facts

Active ingredient (INN)
Ciclesonide
Brand
Alvesco
Strength
160 mcg
Dosage form
Inhaler
Route
Inhalation
Packs
1 inhaler and 1 more
Marketing authorisation holder
Covis Pharma
Manufacturer
Covis Pharma
Origin register
US FDA, United States
Storage
Store at 25°C (77°F). Excursions between 15°C and 30°C (59°F and 86°F) are permitted. For optimal results, the canister should be at room temperature when used. Exposure to temperatures above 49°C (120°F) may cause bursting. Do not use or store near heat or open flame.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
R01AD13 Ciclesonide
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
26 March 2018
Identifiers
RxCUI 799034, 799037, 799038 +1DailyMed set ID 9f6112fb-78ef-43cf-8ae3-36370eb45468NDC 70515-712Application NDA021658

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 inhaler in 1 carton / 60 aerosol, metered in 1 inhaler70515-712-01Covis Pharma26 March 2018
1 inhaler in 1 carton / 30 aerosol, metered in 1 inhaler70515-712-03Covis Pharma30 April 2021
1 inhaler in 1 carton / 30 aerosol, metered in 1 inhaler70515-712-04Covis Pharma30 April 2021
1 inhaler in 1 carton / 60 aerosol, metered in 1 inhaler70515-712-05Covis Pharma30 April 2021

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 20 October 2006Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Ciclesonide

Clinical summary

Ciclesonide is a prescription medicine indicated for treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and perennial allergic rhinitis in adults, among other approved uses. MedsAcross supplies Ciclesonide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Ciclesonide

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Alvesco 160 mcg inhaler for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.